Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.55 |
| ▸ | PNMT | P11086 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27483949 | 0.86 | CES2 (0.55) | AURKAEPHX1PNMTCES2AKR1C3 | |
| SCHEMBL1993610 | 0.85 | AKR1C3 (0.66) | PNMTCES2AKR1C3AKR1C2NPSR1 | |
| SCHEMBL1760202 | 0.85 | AKR1C3 (0.66) | PNMTCES2AKR1C3AKR1C2NPSR1 | |
| SCHEMBL6246702 | 0.84 | PNMT (0.57) | EPHX1PNMTCES2ACP3 | |
| SCHEMBL2510406 | 0.82 | CES2 (0.45) | AURKAEPHX1CES2AKR1C3AKR1C2 | |
| SCHEMBL2486728 | 0.82 | CES2 (0.45) | AURKAEPHX1CES2AKR1C3AKR1C2 | |
| SCHEMBL3143623 | 0.82 | CES2 (0.45) | AURKAEPHX1CES2AKR1C3AKR1C2 | |
| SCHEMBL8234510 | 0.81 | PNMT (0.54) | EPHX1PNMTCES2ACP3 | |
| SCHEMBL5527951 | 0.81 | CES2 (0.67) | EPHX1PNMTCES2ACP3 | |
| SCHEMBL27996637 | 0.81 | PNMT (0.54) | EPHX1PNMTCES2ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1780821-A | Heterocyclic kinase inhibitors. | ABBOTT LAB (US) | 2006-05-31 | — | — | CN | claimed |
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-05-25 | — | — | US | disclosed |
| CN-109153667-A | Novel potassium channel inhibitor | 阿塞西翁制药公司 | 2019-01-04 | — | — | CN | disclosed |
| US-20180371016-A1 | TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-8816119-B2 | Arylamide derivatives having antiandrogenic properties | MEDEIA THERAPEUTICS LTD (FI) | 2014-08-26 | — | — | US | disclosed |
| US-20130109750-A1 | NOVEL ARYLAMIDE DERIVATIVES HAVING ANTIANDROGENIC PROPERTIES | MEDEIA THERAPEUTICS LTD (FI) | 2013-05-02 | — | — | US | disclosed |
| EP-2408754-A1 | Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency | Bayer Pharma Aktiengesellschaft (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2307017-A1 | COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS | Cytomics Systems (FR) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010105750-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
| CN-101541756-A | Pyrazoles as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2009-09-23 | — | — | CN | disclosed |
| CN-1780821-A | Heterocyclic kinase inhibitors. | ABBOTT LAB (US) | 2006-05-31 | — | — | CN | disclosed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HTRA1, HTR3E, HTR1F | AURKA 4592/4885EPHX1 529/4885PNMT 593/4885 |
| US-20180371016-A1 | TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HTRA1, HTR3E, HTR1F | AURKA 4592/4885EPHX1 529/4885PNMT 593/4885 |
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | AURKA 1858/4885EPHX1 870/4885PNMT 1975/4885 |
| US-20130109750-A1 | NOVEL ARYLAMIDE DERIVATIVES HAVING ANTIANDROGENIC PROPERTIES | AR, NR5A1, CYP19A1 | AURKA 1834/4885EPHX1 1377/4885PNMT 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.